| 词条 | MIN-117 |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol[1] | image = MIN-117.svg | width = 250px | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = | CAS_supplemental = | ATC_prefix = | ATC_suffix = | PubChem = 9806065 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 7981825 | C= 25 | H=25 | Cl=2 | N=3 | O=1 | molecular_weight = 502.392 g/mol | SMILES = CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O | StdInChI_Ref = | StdInChI = 1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = XIYDIPLATGRHEC-SFHVURJKSA-N | synonyms = WF-516 }}MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).[2][3][4] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,[4][5][6] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.[3] See also
References1. ^{{cite journal|last1=Kato|first1=Tadafumi|last2=Saijo|first2=Takeaki|last3=Maeda|first3=Jun|last4=Okauchi|first4=Takashi|last5=Maeda|first5=Jun-ichi|last6=Morio|first6=Yasunori|last7=Kuwahara|first7=Yasuhiro|last8=Suzuki|first8=Masayuki|last9=Goto|first9=Nobuharu|last10=Fukumura|first10=Toshimitsu|last11=Suhara|first11=Tetsuya|last12=Higuchi|first12=Makoto|title=Presynaptic Selectivity of a Ligand for Serotonin 1A Receptors Revealed by In Vivo PET Assays of Rat Brain|journal=PLoS ONE|volume=7|issue=8|year=2012|pages=e42589|issn=1932-6203|doi=10.1371/journal.pone.0042589|pmid=22880045|pmc=3413639}} 2. ^{{cite web | title = Minerva Neuroscience | url = http://minervaneurosciences.com/ | accessdate = 2015-05-19}} 3. ^1 {{cite web | title = Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates | author = Minerva Neurosciences | publisher = GlobalNewswire | year = 2015 | url = http://globenewswire.com/news-release/2015/05/07/733476/10133133/en/Minerva-Neurosciences-Reports-First-Quarter-2015-Financial-Results-and-Other-Key-Business-Updates.html | accessdate = 2015-05-19}} 4. ^1 2 {{cite web|title=Investor Presentation March 2015 |author=Minerva Neurosciences |url=http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf |accessdate=2015-05-19 |deadurl=yes |archiveurl=https://web.archive.org/web/20150520033706/http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf |archivedate=2015-05-20 |df= }} 5. ^{{cite web | title = Company Profile for Minerva Neurosciences Inc. | publisher = Reuters | url = http://in.reuters.com/finance/stocks/companyProfile?symbol=NERV.O | accessdate = 2015-05-19}} 6. ^1 {{cite web | title = Some Nerves Surrounding Minerva Neurosciences IPO | author = Don Dion | publisher = Seeking Alpha | year = 2014 | url = http://seekingalpha.com/article/2285733-some-nerves-surrounding-minerva-neurosciences-ipo | accessdate = 2015-05-19}} External links
4 : 5-HT1A antagonists|5-HT2A antagonists|Antidepressants|Serotonin-dopamine reuptake inhibitors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。